Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease
Public ClinicalTrials.gov record NCT00898508. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Blood Tumor Markers for Molecular Diagnosis of Breast Diseases and Monitoring of Breast Cancer Treatment and Follow-up
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Collecting and storing samples of blood and tumor tissue from patients with cancer to test in the laboratory may help the study of cancer in the future. PURPOSE: This clinical trial is studying blood and tumor tissue samples in women with invasive breast cancer, ductal carcinoma in situ, lobular carcinoma in situ, or benign breast disease.
Study identification
- NCT ID
- NCT00898508
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 563 participants
Conditions and interventions
Conditions
Interventions
- gene expression analysis Genetic
- mutation analysis Genetic
- proteomic profiling Genetic
- reverse transcriptase-polymerase chain reaction Genetic
- fluorescent antibody technique Other
- immunohistochemistry staining method Other
- laboratory biomarker analysis Other
- liquid chromatography Other
- mass spectrometry Other
- medical chart review Other
- quality-of-life assessment Procedure
Genetic · Other · Procedure
Eligibility (public fields only)
- Age range
- 20 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 19, 2005 (Actual)
- Primary completion
- Jun 6, 2019 (Actual)
- Completion
- Jun 6, 2019 (Actual)
- Last update posted
- Oct 20, 2026
2005 – 2019
United States locations
- U.S. sites
- 3
- U.S. states
- 1
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Tower Cancer Research Foundation | Beverly Hills | California | 90211 | — |
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010-3000 | — |
| City of Hope Medical Group | Pasadena | California | 91105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00898508, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 20, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00898508 live on ClinicalTrials.gov.